D. E. Shaw & Co., Inc. Fate Therapeutics Inc Call Options Transaction History

D. E. Shaw & Co., Inc.

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $889,000 - $2.12 Million	-50,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$29.67 - $60.28 $1.48 Million - $3.01 Million	50,000 New	50,000 $1.94 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $196M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.